← Back to Search

Cancer Vaccine

M1069 for Solid Tumors

Phase 1
Waitlist Available
Research Sponsored by EMD Serono Research & Development Institute, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new drug called M1069 to see if it is safe and effective for people with advanced solid cancers. Researchers are looking at how the drug moves through the body and interacts with cancer cells. They also want to find out if there are any early signs that it helps treat the cancer.

Eligible Conditions
  • Metastatic or Locally Advanced Unresectable Solid Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: M1069Experimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

EMD Serono Research & Development Institute, Inc.Lead Sponsor
83 Previous Clinical Trials
22,476 Total Patients Enrolled
Merck KGaA, Darmstadt, GermanyIndustry Sponsor
444 Previous Clinical Trials
114,632 Total Patients Enrolled
Medical ResponsibleStudy DirectorEMD Serono Research & Development Institute, Inc.
298 Previous Clinical Trials
60,910 Total Patients Enrolled

Media Library

M1069 (Cancer Vaccine) Clinical Trial Eligibility Overview. Trial Name: NCT05198349 — Phase 1
Solid Tumors Research Study Groups: M1069
Solid Tumors Clinical Trial 2023: M1069 Highlights & Side Effects. Trial Name: NCT05198349 — Phase 1
M1069 (Cancer Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05198349 — Phase 1
~4 spots leftby Nov 2025